Understanding Intraocular Tumors and Your Vision
Understanding Intraocular Tumors
Intraocular tumors are abnormal growths that form within the structures of the eye. They can develop in the uvea (the middle layer of the eye wall, which includes the iris, ciliary body, and choroid), the retina (the light-sensitive tissue at the back of the eye), or other tissues inside the eye. These tumors range from small, slow-growing spots that may only need monitoring to aggressive cancers requiring prompt treatment.
There are several categories of intraocular tumors. The main types include:
- Uveal melanoma: The most common primary eye cancer in adults. Most ocular melanomas originate in the uveal tract, particularly in the choroid (AAO, 2023).
- Retinoblastoma: The most common primary intraocular cancer in children. It develops in the retina and is linked to changes in the RB1 gene.
- Intraocular lymphoma: A cancer involving white blood cells called lymphocytes. It often occurs alongside central nervous system lymphoma.
- Metastatic tumors: Cancer that has spread to the eye from another part of the body. These are the most common intraocular tumors overall.
- Benign tumors: Includes choroidal nevi (eye freckles), choroidal hemangiomas, and other non-cancerous growths that may still need monitoring.
The way a tumor develops depends on the cell type involved. Uveal melanoma arises from melanocytes, the pigment-producing cells within the uveal tract. Researchers have identified specific genetic changes, including mutations in the GNAQ and GNA11 genes, that play a role in tumor formation and growth.
Retinoblastoma develops when both copies of the retinoblastoma gene (RB1) become inactive through mutations. In some children, this gene change is present in every cell of the body, a condition known as heritable retinoblastoma. Intraocular lymphoma involves the uncontrolled growth of lymphocytes within the eye.
Who Is Affected and Risk Factors
Uveal melanoma most commonly affects adults, typically in their 60s. In the United States, choroidal melanoma affects approximately 2,500 people per year, with an incidence of about 6 per million (ASRS). Several characteristics are associated with higher risk:
- Fair skin and light eye color
- Inability to tan
- Ocular or oculodermal melanocytosis
- Presence of cutaneous, iris, or choroidal nevi
- BRCA1-associated protein 1 (BAP1) gene mutation
- Smoking
Retinoblastoma primarily affects young children. The annual incidence rate over a 40-year study period was 12.14 cases per 1 million children aged 4 years or younger (Pubmed, 2018). It accounts for roughly 10 percent of cancers during the first year of life.
The primary risk factor is a change in the RB1 gene. When this genetic change is heritable, it is present throughout the body and can be passed from parent to child. Children with heritable retinoblastoma may develop tumors in both eyes and face a higher lifetime risk of other cancers.
Metastatic intraocular tumors occur in people who have cancer elsewhere in the body. The most common primary cancers that spread to the eye include breast cancer and lung cancer. Any person with a history of systemic cancer should know that vision changes could signal metastasis to the eye.
Intraocular lymphoma tends to affect older adults and those with weakened immune systems. It is closely linked to primary CNS lymphoma. Evaluation may involve both an ocular oncologist and a neurologist or neuro-oncologist.
Signs and Symptoms
Many intraocular tumors are found during routine eye exams before symptoms appear. When symptoms do occur, they tend to be non-specific. Common visual symptoms include floaters (spots or shadows drifting across your vision), flashes of light, and gradual loss of vision in the affected eye.
Decreased visual acuity can result from several mechanisms. The tumor may grow into the area of the retina responsible for central vision. It may also cause cataract formation, fluid buildup in the macula, retinal detachment, or vitreous hemorrhage (bleeding into the gel that fills the eye).
A scotoma is a blind spot or area of reduced vision within your visual field. It develops as the tumor involves the retina near the fovea, the center of the macula responsible for sharp vision. Some patients notice a persistent shadow or missing area in their side vision. These changes may develop gradually and can be easy to overlook at first.
In children, the most recognizable sign of retinoblastoma is leukocoria, a white pupil reflex. This may appear as a white glow in the pupil of one eye, often first noticed in photographs taken with flash. A white or yellowish reflection in a child's eye is not normal and warrants immediate evaluation.
Other signs in children include eyes that appear to look in different directions (strabismus), redness, swelling, or a change in the color of the iris. Any of these findings should prompt a visit to a specialist right away.
Diagnosis and Testing
Diagnosis typically begins with a comprehensive dilated eye examination. A retina specialist or ocular oncologist will use specialized instruments to examine the inside of the eye in detail. This exam can reveal the presence, size, location, and characteristics of a tumor. Many intraocular tumors, especially choroidal nevi, are first detected during routine dilated exams.
Several imaging techniques help specialists evaluate intraocular tumors with precision. These include:
- Optical coherence tomography (OCT): Provides cross-sectional images of the retina and can detect fluid or subtle structural changes caused by a tumor.
- Fundus photography: Creates detailed photographs of the inside of the eye to document the tumor's appearance over time.
- Ultrasound (B-scan): Uses sound waves to measure tumor thickness and examine the internal structure of the mass.
- Fluorescein angiography: Involves injecting a dye into a vein to highlight blood vessel patterns in and around the tumor.
Improved methods of intraocular biopsy now allow specialists to obtain small tissue samples from eye tumors for analysis. Molecular genetic testing of these samples has become an important part of diagnosis and prognosis, particularly for uveal melanoma.
Prognostic testing can identify chromosomal abnormalities that predict whether a uveal melanoma has a high potential to spread to other parts of the body. This information helps guide treatment planning and the frequency of follow-up care.
Treatment Options
Radiation therapy is the most widely used treatment for uveal melanoma. Plaque brachytherapy involves placing a small radioactive disc on the outside wall of the eye directly over the tumor. The plaque delivers targeted radiation over several days and is then removed.
Teletherapy delivers radiation from an external source. Options include proton beam therapy, helium ion radiation, and stereotactic radiosurgery. The goal of radiation therapy is to destroy the tumor while preserving as much healthy eye tissue and vision as possible.
Laser approaches are typically offered as primary treatments for small ocular melanomas. These procedures use focused light energy to destroy tumor cells. Photodynamic therapy (PDT) uses a light-activated drug to target tumor tissue. These therapies may be used alone or combined with other treatments depending on tumor size, location, and characteristics.
Surgical options include vitrectomy (surgery to remove the gel inside the eye) and tumor resection (direct removal of the tumor). In cases where the tumor is very large, has caused extensive damage, or poses a significant risk to the patient's life, enucleation (surgical removal of the entire eye) may be recommended.
Enucleation is generally considered a last resort when other treatments cannot safely control the tumor. After enucleation, a prosthetic eye can be fitted for cosmetic appearance.
Treatment for retinoblastoma has advanced significantly. Local techniques now play a prominent role. These include plaque brachytherapy, intra-arterial chemotherapy (delivering drugs directly to the eye through a blood vessel), and intravitreal chemotherapy (injecting drugs directly into the eye). These targeted approaches aim to destroy the tumor while reducing side effects.
The choice of treatment depends on the size and location of the tumor, whether one or both eyes are affected, and whether the cancer has spread beyond the eye.
Intraocular lymphoma may be treated with intravitreal methotrexate (a chemotherapy drug injected directly into the eye). Because intraocular lymphoma is often associated with CNS lymphoma, treatment may also involve systemic chemotherapy or radiation therapy to the brain, coordinated between multiple specialists.
What to Expect During Treatment
After an intraocular tumor is detected, you can expect a thorough evaluation that may include multiple imaging tests and possibly a biopsy. Your retina specialist or ocular oncologist will explain the type, size, and location of the tumor. For uveal melanoma, molecular genetic testing may be recommended to assess metastatic risk.
Treatment planning is individualized. The specialist will discuss the most appropriate options, including expected benefits, potential risks, and likely impact on vision.
Follow-up care after treatment is essential. Monitoring typically includes regular dilated eye exams, imaging studies, and in some cases systemic evaluations to check for cancer spread. The frequency of follow-up depends on the type of tumor and the treatment received.
Vision outcomes vary widely depending on tumor type, size, and location, as well as the treatment used. Some patients retain good vision after treatment, while others may experience partial or significant vision loss. Your specialist will provide realistic expectations based on your individual case.
A diagnosis of an intraocular tumor can be emotionally challenging. It is normal to feel anxious, overwhelmed, or uncertain about the future. Many patients benefit from connecting with support groups, counseling services, or patient advocacy organizations that specialize in ocular cancers. Your care team can help direct you to these resources.
Follow-Up and Monitoring
Many intraocular tumors require long-term monitoring, including choroidal nevi and small melanomas treated with radiation. Even after successful treatment, regular check-ups help detect any changes early. For uveal melanoma, systemic monitoring (often including liver imaging) is recommended because metastasis can occur years after diagnosis.
Protecting your remaining vision is an important part of living with an intraocular tumor. Wearing sunglasses to shield your eyes from ultraviolet light, attending all scheduled follow-up appointments, and reporting any new visual symptoms promptly can all help. If vision has been significantly affected, low-vision rehabilitation services can help you adapt and maintain independence.
When to See a Retina Specialist
Certain symptoms require immediate evaluation. See a retina specialist or go to the emergency room right away if you experience a sudden increase in floaters, new flashes of light, a curtain or shadow over your vision, or sudden vision loss in one eye. These symptoms could indicate a serious complication such as retinal detachment or vitreous hemorrhage.
If a growth or suspicious finding is detected during a routine eye exam by an optometrist or general ophthalmologist, a referral to a retina specialist or ocular oncologist is the next step. Adults with known risk factors for uveal melanoma should discuss screening schedules with their eye care provider.
Parents who notice a white reflex in the pupil, crossed eyes, or other unusual eye appearance in their child should seek evaluation promptly. Early detection of retinoblastoma is critical for preserving vision and protecting the child's health.
Questions and Answers
Yes. Many intraocular tumors, including choroidal melanoma and choroidal nevi, are found during routine dilated eye examinations before a patient notices any visual changes. This is one of the most important reasons to have regular comprehensive eye exams, especially for adults over 50 and those with known risk factors. Early detection provides more treatment options and may improve outcomes.
Enucleation (removal of the eye) is not the only treatment option. It is generally reserved for large tumors or cases where other treatments cannot safely control the cancer. Many intraocular tumors can be treated with radiation therapy, laser treatment, or localized chemotherapy while preserving the eye. Your retina specialist or ocular oncologist will recommend the approach that best balances tumor control with vision preservation.
Retinoblastoma can be hereditary. In heritable retinoblastoma, a change in the RB1 gene is present in all cells of the body. This form can be passed from parent to child. It is associated with tumors in both eyes and an increased risk of other cancers later in life. Genetic counseling is recommended for families affected by retinoblastoma.
Follow-up schedules vary based on tumor size, genetic profile, and the treatment used. Most patients will have eye exams and imaging studies every three to six months for the first several years. Because uveal melanoma can spread to the liver and other organs, systemic monitoring is typically recommended at regular intervals. Your specialist will create a surveillance plan tailored to your risk profile based on molecular genetic testing results.
A white glow or white reflex in a child's pupil, known as leukocoria, should be evaluated by a specialist as soon as possible. While not every case of leukocoria indicates retinoblastoma, it is one of the most recognizable early signs of this childhood eye cancer. Early diagnosis and treatment are critical for preserving vision and protecting the child's health. Contact your child's pediatrician or an eye specialist right away.